PP
ADPT icon

Paloma Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Paloma Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-41,484
Closed -$2.01M – 2026
2020
Q2 		$2.01M Buy
+41,484
New +$1.51M 0.03% 625

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Paloma Partners's ADPT Position: Q3 2020 in Review

Paloma Partners sold out of Adaptive Biotechnologies (ADPT) in Q3 2020, closing a stake of 41,484 shares — an estimated $2.01M sold.

Paloma Partners first reported a position in ADPT in Q2 2020 and held it in 1 quarter. The position peaked at $2.01M in Q2 2020. 206 funds tracked by Wall St. Rank hold ADPT as of Q3 2020.

  • Paloma Partners reported no remaining Adaptive Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 41,484 Adaptive Biotechnologies shares in Q3 2020, an estimated $2.01M.
  • Paloma Partners first reported a position in Adaptive Biotechnologies in Q2 2020 and held it in 1 quarter.
  • Paloma Partners's Adaptive Biotechnologies position peaked at $2.01M in Q2 2020.
  • 206 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.